While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

VINORELBIN
Home >> Search Drug By Letter >> Search Drug By Letter: V >> VINORELBIN
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

VINORELBIN
 
 
Package(a):
VIALS: 1 x 10 mg/ml.
Dosage(a):
I.V. use. Adjust according to indication, general condition, hepatic and renal function, concurrent chemotherapy and blood counts. See prescribing information for full details.
Prescribing Restrictions: Kupah Pharmacy Only Medical Division Approval 

Package(b):
VIALS: 1 x 50 mg/5 ml.
Dosage(b):
I.V. use. Adjust according to indication, general condition, hepatic and renal function, concurrent chemotherapy and blood counts. See prescribing information for full details.
Prescribing Restrictions:   Kupah Pharmacy Only Medical Division Approval 


Indications:
The treatment of non small cell lung cancer. The treatment of advanced breast cancer. Hormone-refractory prostate cancer, especially in combination with low dose oral corticoid therapy or Estramustin.
Contra-Indications:
Hypersensitivity to vinorelbine, other vinca alkaloids or to any of the constituents. Neutrophil counts below 2,000/mm3. Intrathecal administration. Severe infection current or recent. Intrathecal administration. Pregnancy and lactation, severe hepatic insufficiency. Patients with pre-treatment granulocyte counts <1,000 cells mm3. See prescribing information for full details.
Special Precautions:
Hospital use only. Should be administered by or under supervision of physicians expereinced in the use of cancer chemotherapeutic agents. Patients should be frequently monitored for myelosuppression during and after therapy. Granulocytopenia is dose limiting. Granulocyte nadirs occur between 7 and 10 days after dosing with granulocyte count recovery usually within the following 7 to 14 days. Complete blood counts with differentials should be performed prior to administering each dose. Should not be prescribed in combination with liver radiotherapy. Patients with renal insufficiency. 
Pediatric use: Doses similar to those used in adults is usually well tolerated with similar toxicity to those reported in adults.
Side Effects:
Granulocytopenia, loss of deep tendon reflexes. Shortness of breath, dyspnea and bronchospasms. Leakage into surrounding tissue during I.V. administration may cause local reaction. Chemical phlebitis along the vein proximal to the site of injection. Alopecia, sensation of pain in the jaws. Constipation, diarrhea, nausea, vomiting.
Drug Interactions:
There are no known drug interactions.